Peptide Selank Reduces Anxiety and Pain During Alcohol Withdrawal in Rats

Alcohol Use Disorder (AUD) is a chronic relapsing brain disease, and a significant barrier to recovery is the severe discomfort of Alcohol Withdrawal Syndrome (AWS). Symptoms like anxiety, tremors, and hyperalgesia (increased pain sensitivity) can be debilitating and drive relapse. Current treatments often have their own side effects or abuse potential. This study addresses the urgent need for novel, non-addictive therapeutic strategies to alleviate the acute symptoms of alcohol withdrawal, specifically focusing on anxiety and pain without impacting alcohol consumption itself.

The study revealed that a single dose of Selank at 0.3 mg/kg significantly mitigated the severe symptoms of acute alcohol withdrawal in rats. In the elevated plus maze, Selank-treated animals showed a marked reduction in anxiety-like behaviors compared to untreated withdrawal controls. Similarly, in social interaction tests, the peptide effectively eliminated the anxiety typically induced by 48-hour ethanol withdrawal. The researchers also observed that Selank prevented the development of mechanical allodynia, a painful hypersensitivity often associated with withdrawal, indicating a broader analgesic effect. The most important finding was that Selank at 0.3 mg/kg completely eliminated anxiety induced by ethanol withdrawal and prevented the formation of mechanical allodynia, without affecting the rats' subsequent 10% ethanol consumption. This suggests Selank specifically targets withdrawal symptoms rather than inducing general sedation or altering alcohol preference.